


Engineered skeletal muscle recapitulates human muscle development, regeneration and dystrophy

Mina Shahriyari^{1,2}, Md Rezaul Islam³, Sadman M. Sakib³, Malte Rinn^{1,2}, Anastasia Rika^{1,2}, Dennis Krüger³, Lalit Kaurani³, Verena Gisa³, Mandy Winterhoff^{1,2}, Harithaa Anandakumar^{1,2}, Orr Shomroni⁴, Matthias Schmidt⁵, Gabriela Salinas⁴, Andreas Unger⁶, Wolfgang A. Linke⁶, Jana Zschüntzsch⁵, Jens Schmidt^{5,7,8}, Rhonda Bassel-Duby^{9,10,11}, Eric N. Olson^{9,10,11}, André Fischer^{3,12}, Wolfram-Hubertus Zimmermann^{1,2,12,13*} & Malte Tiburcy^{1,2*} 

¹Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg August University, Göttingen, Germany; ²DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Göttingen, Germany; ³Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany; ⁴NGS Integrative Genomics Core Unit, Institute of Human Genetics, University Medical Center Göttingen, Georg August University, Göttingen, Germany; ⁵Department of Neurology, Neuromuscular Center, University Medical Center Göttingen, Georg August University, Göttingen, Germany; ⁶Institute of Physiology II, University of Münster, Münster, Germany; ⁷Department of Neurology and Pain Treatment, Immanuel Klinik Rüdersdorf, University Hospital of the Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany; ⁸Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany; ⁹Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA; ¹⁰Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; ¹¹Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; ¹²Cluster of Excellence 'Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells' (MBExC), University of Göttingen, Göttingen, Germany; ¹³Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Göttingen, Germany

Abstract

Background Human pluripotent stem cell-derived muscle models show great potential for translational research. Here, we describe developmentally inspired methods for the derivation of skeletal muscle cells and their utility in skeletal muscle tissue engineering with the aim to model skeletal muscle regeneration and dystrophy in vitro.

Methods Key steps include the directed differentiation of human pluripotent stem cells to embryonic muscle progenitors followed by primary and secondary foetal myogenesis into three-dimensional muscle. To simulate Duchenne muscular dystrophy (DMD), a patient-specific induced pluripotent stem cell line was compared to a CRISPR/Cas9-edited isogenic control line.

Results The established skeletal muscle differentiation protocol robustly and faithfully recapitulates critical steps of embryonic myogenesis in two-dimensional and three-dimensional cultures, resulting in functional human skeletal muscle organoids (SMOs) and engineered skeletal muscles (ESMs) with a regeneration-competent satellite-like cell pool. Tissue-engineered muscle exhibits organotypic maturation and function (up to 5.7 ± 0.5 mN tetanic twitch tension at 100 Hz in ESM). Contractile performance could be further enhanced by timed thyroid hormone treatment, increasing the speed of contraction (time to peak contraction) as well as relaxation (time to 50% relaxation) of single twitches from 107 ± 2 to 75 ± 4 ms ($P < 0.05$) and from 146 ± 6 to 100 ± 6 ms ($P < 0.05$), respectively. Satellite-like cells could be documented as largely quiescent PAX7⁺ cells ($75 \pm 6\%$ Ki67⁻) located adjacent to muscle fibres confined under a laminin-containing basal membrane. Activation of the engineered satellite-like cell niche was documented in a cardiotoxin injury model with marked recovery of contractility to $57 \pm 8\%$ of the pre-injury force 21 days post-injury ($P < 0.05$ compared to Day 2 post-injury), which was completely blocked by preceding irradiation. Absence of dystrophin in DMD ESM caused a marked reduction of contractile force ($-35 \pm 7\%$, $P < 0.05$) and impaired expression of fast myosin isoforms resulting in prolonged contraction (175 ± 14 ms, $P < 0.05$ vs. gene-edited control) and relaxation (238 ± 22 ms, $P < 0.05$ vs. gene-edited control) times. Restoration of dystrophin levels by gene editing rescued the DMD phenotype in ESM.

Conclusions We introduce human muscle models with canonical properties of bona fide skeletal muscle in vivo to study muscle development, maturation, disease and repair.

Keywords Duchenne muscular dystrophy; hypaxial dermomyotome; limb muscle; satellite cells; skeletal muscle organoid; somite; tissue engineering

Received: 9 March 2022; Revised: 29 July 2022; Accepted: 10 September 2022

*Correspondence to: Malte Tiburcy and Wolfram-Hubertus Zimmermann, Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg August University, Robert-Koch-Str. 40, 37075 Göttingen, Germany. Email: m.tiburcy@med.uni-goettingen.de; w.zimmermann@med.uni-goettingen.de

Introduction

Pluripotent stem cell (PSC)-derived organotypic cultures with structural and functional properties of native human tissue are increasingly utilized for disease modelling and drug screening applications. Organotypic skeletal muscle cultures are highly sought after, because of the central role of skeletal muscle in disease (e.g., myopathies) and drug effects (e.g., insulin). Early studies have demonstrated that it only requires MyoD overexpression in fibroblasts to activate myogenic programmes.¹ Muscle stem cells can also be isolated from muscle biopsies, but rapidly lose their stem cell properties with expansion often requiring immortalization to provide consistent cell quantity and quality.^{2,3} Derivation of skeletal muscle cells from human PSC (hPSC) can in principle overcome this limitation and combined with tissue/organoid engineering methods may allow for an emulation of embryonic myogenesis from a cell to tissue level.

The derivation of skeletal muscle cells from PSC has been demonstrated previously by either transfection or transduction of myogenic transgenes^{4–10} or directed, transgene-free differentiation under controlled growth factors or small-molecule stimulation.^{11–17} Recently, more advanced neuromuscular organoids have been introduced that recapitulate characteristic steps of embryonic neuromuscular co-development.^{18,19} These innovative cell models have shown potential for preclinical modelling of human neuromuscular disease, such as laminopathies,^{20,21} Duchenne muscular dystrophy (DMD)^{14,21–24} and myasthenia gravis.^{18,25}

Several studies have applied tissue engineering methods to generate skeletal muscle from hPSC-derived cells in vitro,^{6,21,26} collectively suggesting a potential of 3D skeletal muscle for disease modelling and regenerative medicine. However, the functional output of in vitro muscle is still far from postnatal muscle even though improvements have been demonstrated using a specific cell culture supplement.²⁶ For the only transgene-free model published so far, muscle function was not reported.²¹ In a previous study using rat primary myocytes, our group demonstrated that the application of collagen/Matrigel® hydrogels in combination with isometric loading generates engineered skeletal muscle (ESM) with physiological function and a regenerative satellite cell niche in vitro.²⁷

Here, we report a transgene-free and serum-free human muscle protocol that closely follows developmental trajectories to induce somitogenesis and muscle formation in 2D and 3D. Human ESMs respond to developmentally relevant cues, such as triiodothyronine, with advanced maturation, demonstrating physiological growth potential, and display functional regeneration by satellite-like cells in vitro. In addition, ESMs recapitulate the contractile deficit of DMD and its rescue by CRISPR/Cas9 myoediting.

Methods

Generation of skeletal muscle from human pluripotent stem cells

Human PSC lines (please see Methods in the supporting information for details) were maintained on 1:120 Matrigel™ (BD) in phosphate-buffered saline (Thermo Fisher Scientific)-coated plates and cultured in StemMACS iPS-Brew XF (Miltenyi Biotec) at 37°C and 5% CO₂.

For skeletal muscle differentiation in 2D, 1.3×10^4 to 2.1×10^4 cells/cm² PSC were seeded in iPS-Brew XF medium with 5 µmol/L of Y27632 (Stemgent) for 24 h. iPS-Brew XF medium was then replaced with daily refreshed N2-CLF medium for 4 days. N2-CLF medium consisted of DMEM (Thermo Fisher Scientific) with 1% Pen/Strep, 1% N-2 Supplement and 1% MEM non-essential amino acid solution (N2 basal medium, all Thermo Fisher Scientific), 10 µmol/L CHIR99021 (Stemgent), 0.5 µmol/L LDN193189 (Stemgent) and 10 ng/mL FGF-2 (PeproTech). At Day 4, the medium was exchanged with N2-FD medium every 24 h until Day 6. N2-FD medium contained N2 basal medium, 20 ng/mL FGF-2 and 10 µmol/L DAPT (Tocris). For Days 6 and 7, the medium was replaced with N2-FDH (N2 basal medium, 20 ng/mL FG8F-2, 10 µmol/L DAPT and 10 ng/mL HGF [PeproTech]). The medium was switched to N2-DHK medium on Days 8, 9, 10 and 11 (N2 basal medium, 10 µmol/L DAPT, 10 ng/mL HGF and 10% knockout serum replacement [Thermo Fisher Scientific]). From Days 13 to 22, myogenic cells were cultured in expansion medium (N2 basal medium, 10% knockout serum replacement and 10 ng/mL HGF). To further differentiate the cells in monolayer culture, Day 22 skeletal myocytes were enzymatically dissociated with TrypLE (Thermo Fisher Scientific) for 5 to 7 min at 37°C and replated on 1:120 Matrigel™-coated plates at a density of 60 000–70 000 cells/cm² in expansion medium with 5 µmol/L Y27632 (Stemgent). Skeletal myocyte maturation was done in DMEM with 1% Pen/Strep, 1% N-2 Supplement and 2% B-27 Supplement (maturation medium).

To generate SMOs in 3D, 0.8×10^6 PSCs resuspended in 157.5 µL of StemMACS iPS-Brew XF medium with 5 µmol/L Y27632, 10 ng/mL FGF-2 and 10% knockout serum replacement were cast into a hydrogel as a 250 µL volume reconstitution mixture comprised of (i) 36 µL of 6.5 mg/mL (final amount of 0.23 mg) acid soluble collagen type 1 (LLC Collagen Solutions), (ii) 36 µL of concentrated 2× DMEM (Thermo Fisher Scientific) serum-free medium, (iii) 6.75 µL of NaOH 0.1 N (Carl Roth) and (iv) 10% v/v Matrigel™ (BD). PSCs in hydrogel were then differentiated as outlined above for 2D cells.

To make ESM, 1.25×10^6 of Day 22 PSC-derived skeletal myocytes, which were resuspended in 157.5 µL of expansion medium with 5 µmol/L Y27632, were cast into a hydrogel with

a final 250 μL per ESM volume mixture of (i) 36 μL of 6.5 mg/mL (final amount of 0.23 mg) acid soluble collagen type 1, (ii) 36 μL of concentrated 2 \times DMEM medium, (iii) 6.75 μL of NaOH 0.1 N and (iv) 10% v/v Matrigel™ (please see Methods in the supporting information for details).

Statistical analysis

Data were analysed using GraphPad Prism 7 software and presented as mean \pm SEM. Statistical analyses were done using unpaired, two-tailed, Student's *t* test and one-way or two-way ANOVA with specified multiple comparison tests where appropriate (please refer to figure legends). $P < 0.05$ was considered significant. *n* indicates the number of biological replicates.

Please see Methods in the supporting information for further experimental details.

Results

Embryonic myogenesis by directed differentiation of human pluripotent stem cells in 2D and 3D

To robustly generate human skeletal muscle, we adapted several principles previously identified to be crucial for directed skeletal muscle differentiation (final optimized protocol in Figure 1A).^{12,14,17,28} As 2D cultures of skeletal myocytes do not develop the spatial and structural organization of skeletal muscle in vivo,²⁵ we also investigated if muscle differentiation could be recapitulated in a 3D format. To test this, we embedded undifferentiated induced (iPSC) in a collagen/Matrigel hydrogel to obtain SMOs (Figure 1A). We first asked if the temporal sequence of muscle cell development was comparable to parallel 2D differentiation. RNA expression analyses showed a similar decrease in pluripotency gene (*POU5F1*) and increase of paraxial mesoderm gene (*TBX6*) expression by a modification of BMP (inhibition) and Wnt (activation) signalling with 0.5 $\mu\text{mol/L}$ LDN 193189 and 10 $\mu\text{mol/L}$ CHIR99021.^{11,12} Following paraxial mesoderm induction, the expression of *PAX3* and *SIM1* in the presence of FGF2, HGF¹² and Notch 1 inhibition with DAPT (10 $\mu\text{mol/L}$; γ -secretase inhibition¹⁴) was an indication of somitogenesis with an enhanced expression of dermomyotomal progenitor cell transcripts (*PAX3* and *SIM1*) in SMO. Interestingly, low expression of *EN1* at the peak of *SIM1* expression (Day 13) may indicate a predominantly hypaxial dermomyotomal progenitor pattern.²⁹ This was followed by a largely comparable emergence of muscle progenitor transcripts *PAX7*, *MYOD1*, *MYOG* and *MYMK*; *MYOD1* expression remained more abundant at Day 50 in SMO. In addition, robust increases in *ACTN2*, *ENO3* and *MYH8* expression suggested emergence

of myocytes and secondary myogenesis between Days 22 and 52, which was enhanced in SMO (Figure 1B). The temporal transcriptome changes were corroborated by immunostaining demonstrating the loss of OCT4, appearance of muscle progenitor populations expressing *PAX3* and *LBX1* at Days 8 and 13 followed by consecutive appearance of *PAX7*⁺, *MYOD1*⁺, *MYOG*⁺ and *ACTN2*⁺ myocytes in 2D and SMO cultures (Figure S1).

To obtain more insight into the global developmental patterns of the skeletal muscle differentiation protocol in vitro, we subjected RNAseq data obtained at selected time points in 2D differentiation to bioinformatic analyses (Figure 2A). Unbiased clustering separated the distinct time points into mesoderm induction (Days 0, 1 and 4), myogenic specification (Days 8 and 13), early (Days 22 and 29) and advanced (Day 60) myogenic maturation (Figure 2B). Further clustering the genes by weighted co-expression analysis identified 22 gene clusters with remarkable overlap to the biological processes of skeletal muscle differentiation characterized by the expression of developmental signature genes reflecting primitive streak formation (cluster #10), paraxial mesoderm formation and patterning (clusters #15, 19 and 22), formation of dorsal (dermomyotome) and ventral somite (sclerotome, cluster #3), migrating limb progenitors (cluster #1), sarcomere formation (cluster #8) and muscle maturation (cluster #5; Figure 2C,D and Table S1).

We next asked if the identified gene clusters overlap with developmentally regulated genes of human embryonic muscle making use of a published data set (GSE90876¹³). Interestingly, several of the bioinformatically identified clusters from skeletal myogenesis in vitro showed significant overlap with embryonic development in vivo (Figure 2E). We then utilized the co-expression analysis to dissect processes coinciding with muscle maturation (cluster #5) to extract information to support muscle maturation in vitro. Interestingly, cluster #5 was highly enriched in signalling transcripts (Figure 2F). Among them, we identified several signalling pathways that have been associated with muscle maturation such as *NRG1*, *IGF1/VEGF* and thyroid hormone indicating that our protocol emulates central mechanisms of muscle development in vivo. In summary, we demonstrate the successful recapitulation of key developmental stages of human embryonic muscle development in 2D and in a 3D organoid approach (SMO).

Generation of skeletal muscle with organotypic function

As both 2D myocytes (Video S1) and SMO cultures (Video S2) demonstrated contractile activity, we further investigated if skeletal muscle tissue with skeletal muscle-specific function can be generated from hPSC. Although SMOs recapitulate the embryonic muscle development in 3D, we tested the




Figure 1 Skeletal myocyte differentiation from human pluripotent stem cells (PSCs) in 2D and 3D cultures. (A) Summary of the protocol for directed skeletal muscle differentiation from PSCs indicating the sequence and the timing of factor addition to modulate specific signalling pathways involved in skeletal myogenesis. Skeletal muscle organoids (SMOs) were generated from induced PSC (iPSC) mixed with collagen type 1 and Matrigel™ in a ring-shaped hydrogel. After consolidation in PDMS casting moulds, SMOs were directed towards skeletal muscle using the indicated protocol established in 2D monolayer cultures. Scale bars: 5 and 1 mm (3D panels); 50 μ m (2D panels). (B) Transcript levels (RNA counts measured by nCounter) of signature genes for pluripotency (*POU5F1*), paraxial mesoderm (*TBX6*), somitogenesis (*PAX3*, *SIM1* and *EN1*), myogenic transcription factors (*PAX7*, *MYOD1* and *MYOG*), structural assembly (*MYMK* and *ACTN2*) and secondary myogenesis (*ENO3* and *MYH8*) during skeletal muscle differentiation from human PSCs in SMO and 2D; $n = 3-5$ per time point and group, $P < 0.05$ by two-way analysis of variance (ANOVA) and Sidak's multiple comparison test




Figure 2 Developmental transcriptome patterns in pluripotent stem cell (PSC) skeletal myocyte differentiation. (A) Scheme of skeletal muscle differentiation from human PSCs (HES2) with sampling time points for RNA sequencing. (B) Unsupervised clustering of the samples from different time points. (C) Weighted co-expression analysis identified 22 clusters of genes with similar expression dynamics (co-expression clusters); a heatmap of mean eigenvalues is displayed. (D) Normalized expression levels (reads per kilobase million [RPKM]) of indicated signature genes in identified co-expression clusters, $n = 2-4$ per time point. (E) Developmentally regulated genes were identified based on a published human embryonic muscle data set.¹³ The table indicates the overlap of co-expression cluster genes to genes regulated between presomitic mesoderm (PSM) and nascent somite (SM) or presomitic mesoderm (PSM) and developed somite (Dev SM). Overlap is graded as either not significant (n.s.), $*P < 0.05$, $**P < 0.01$ or $***P < 0.001$ by Fisher's exact test. The colour codes for the number of overlapping genes. As differentially expressed genes were obtained by comparing to SM and Dev SM to PSM, preceding developmental processes (i.e., paraxial mesoderm formation and earlier) are not represented in the embryo data set and therefore cannot overlap with *in vitro* processes (labelled as not applicable, n.a.). Clusters that were not muscle related and did not significantly overlap were omitted. (F) Gene Ontology (GO) terms specifically enriched in co-expression cluster #5 (top panel). List of genes associated with 'regulation of signaling' in co-expression cluster #5 (bottom panel)

controlled assembly of differentiated PSC-derived skeletal myocyte populations obtained from 2D directed differentiation into ESM as an alternative approach. Day 22 myocytes (identified as optimal time point based on palpable expression of MRFs and ACTN2, *Figure 1B*) were dissociated and allowed to self-organize after suspension in a collagen/Matrigel™ hydrogel and transfer into a circular casting mould (*Figure 3A*). Immunostaining of the Day 22 input cell populations revealed a cell composition consisting of $43 \pm 4\%$ PAX7⁺, $52 \pm 2\%$ MYOD1⁺ and $49 \pm 4\%$ MYOGENIN⁺ ($n = 9\text{--}13$ differentiations; *Figure S2A*). Flow cytometry showed comparable efficiency for one human embryonic stem cell (HESC) and four different iPSC lines, supporting the robustness and reproducibility of the protocol (*Figure S2B*). After formation of a compact tissue ring (after 4–7 days), ESMs were transferred to metal holders for further maturation (*Figure 3A*). After 1–2 weeks, spontaneous contractions were observed in ESM (*Video S3*).

SMOs and ESMs demonstrated robust force generation after 4 weeks of maturation. At 1 Hz electrical stimulation, SMOs and ESMs generated single twitches, whereas at higher frequencies, tetanic contractions were observed, which were maximal at 100 Hz and significantly stronger in ESM (2.8 ± 0.2 vs. 1.2 ± 0.1 mN in SMO, $n = 11/15$; *Figure 3B,C*). The cross-sectional area populated with muscle cells tended to be lower in SMO compared to ESM ($48 \pm 3\%$ vs. $58 \pm 3\%$ [$n = 3$]). In addition, the diameter of the myofibres was significantly smaller in SMO compared to ESM, likely explaining the differences in function (*Figure 3D,E*). The difference in maturation was further supported by higher expression of embryonic myosin (*MYH3*), lower expression of perinatal myosin (*MYH8*) and higher expression of cell cycle (*CDK1*) and muscle progenitor transcripts (*PAX7*, *MYOD1* and *MYOG*) in SMO compared to ESM (*Figure 3F*). Collectively, both tissue engineering approaches (SMO and ESM) yield skeletal muscle with physiological function, with enhanced skeletal muscle maturation in ESM.

Next, we were interested if the ESM protocol is in principle suitable to generate skeletal muscle from human primary skeletal myocytes (pSkMs) and how it compares to PSC-derived ESM. Although force-generating tissue was uniformly generated, we noticed lower force development (0.4 ± 0.1 vs. 2 ± 0.3 mN, $n = 6/3$ in pSkM ESM vs. PSC ESM) and high functional inter-patient variability in pSkM ESM (*Figure S3A,B*). As muscle-related genes were mostly more abundant in pSkM ESM (*Figure S3C*), we hypothesized that the lack of mesenchymal support cells may contribute to the lower function in pSkM ESM. To test this, we sorted mesenchymal cells (MCs) from PSC skeletal myocyte cultures and obtained an ~80% pure population of PDGFRA⁺ and FAP⁺ MC. Primary skeletal myocytes were then mixed with isolated PSC MC and compared to non-MC-supplemented ESM (*Figure S3D*). MC supplementation increased the twitch tension by 3.5 ± 0.1 -fold ($n = 4$, $P < 0.05$) indicating

that the MC population supports muscle development (*Figure S3E*).

Essential cellular heterogeneity as a result of directed myogenesis in vitro

Skeletal muscle differentiation in PSC yields heterogeneous cell populations, which may be beneficial for muscle formation in vitro as demonstrated for a sorted MC fraction (*Figure S3*). We performed single-nucleus RNA sequencing to investigate whether our directed differentiation recapitulates development of the heterologous muscle cell populations found in bona fide skeletal muscle. We investigated Day 22 cultures as input cell population for ESM and compared it with later stage cultures in 3D (SMO and ESM after 4 weeks of maturation) or parallel 2D cultures (2D Day 60). The temporal difference in development between D22 and D60 cultures was clearly reflected by separation of the corresponding populations (*Figure 4A*). Importantly, the D22 cultures from two experimental runs ($n = 9253$ cells in total) were largely overlapping, supporting the robustness of the differentiation protocol in generating comparable cell populations (*Figure 4A*). Unsupervised clustering of all samples identified 19 different cell population of which clusters #1, 3, 8, 11, 12 and 16 were enriched in muscle genes, clusters #0, 2, 4, 5, 6, 14, 15, 17 and 19 were enriched in mesenchymal genes and clusters #7, 9, 10, 13 and 18 were enriched in neural genes (*Figure 4B,C*). Comparison of the contribution of each sample to the identified 19 clusters revealed clusters that were overrepresented in either 2D or 3D cultures. In line with the developmental trajectories, a myogenic progenitor (MP) population enriched in PAX3⁺, PAX7⁺, SIM1⁺ and MET⁺ cells was only identified in the D22 cultures (#1). A matured population of myonuclei (#3: MYH8⁺, ENO3⁺ and ACTA1⁺) was only found in D60 cultures. Of note, higher expression levels and more frequent contribution to cluster #3 in 3D (SMO and ESM) versus 2D cultures support enhanced maturation in 3D (*Figure 4D,E*). Interestingly, cluster #11, which was also predominantly found in 3D cultures, was highly enriched in satellite cell markers (*PAX7*, *ITGA7*, *CALCR*, *EGFR* and *DLK1*) and inhibitors of cell cycle (*CDKN1C*) implicating a satellite-like cell population (*Table S2*).

A mesenchymal population (#2) enriched in PDGFRA⁺, EBF2⁺, FAP⁺, MEOX2⁺ and TWIST1⁺ cells was found in 2D Day 22 and similarly in SMO (#17) and 2D Day 60 (#6) cultures. In ESM, there was an apparent enrichment of MC populations (#4 and 14) with enhanced expression of ECM-related genes (*COL1A1* and *FN1*). In SMO, two specific populations were identified. Cluster #5 showed persistent expression of sclerotome marker genes (*SOX9* and *MDF1*), whereas cluster #19 showed high expression of epidermal marker *KRT19*.




Figure 3 Advanced development of skeletal muscle function in human engineered skeletal muscle (ESM). (A) Scheme of ESM generation from human PSC-derived skeletal myocytes with collagen type 1 and Matrigel™ in a ring-shaped hydrogel. ESM formation in expansion medium for 1 week in PDMS casting moulds, functional maturation under isometric mechanical load (ESM on metal hooks). Scale bar: 5 mm. (B) Representative original recordings of single twitches at 1 Hz and tetanic contraction at 100 Hz of skeletal muscle organoid (SMO) (black lines) and ESM (blue lines). (C) Twitch tension in response to increasing stimulation frequencies of SMO (black bars) and ESM (blue bars) after 4 weeks of maturation; $n = 15$ for SMO and $n = 11$ for ESM, $^*P < 0.05$ by two-way analysis of variance (ANOVA) and Tukey's multiple comparison test. (D) Immunostaining of ACTIN⁺ muscle cells (green) in cross sections and longitudinal sections of SMO and ESM after 4 weeks of maturation. Scale bar: 500 μ m (A, C) and 20 μ m (B, D). (E) Myofibre diameter distribution in SMO and ESM after 4 weeks of maturation. (F) Transcript levels (RNA counts measured by nCounter) of indicated muscle genes in SMO and ESM, $n = 7/3$ (SMO/ESM), $^*P < 0.05$ by two-way ANOVA and Sidak's multiple comparison test




Figure 4 Cellular composition of differentiated skeletal myogenic cultures in 2D and 3D. (A) Unsupervised clustering (Uniform Manifold Approximation and Projection [UMAP]) of single-nucleus transcriptomes. Colour coding indicates different input samples (2D Day 22 skeletal muscle cultures, 2D Day 60 skeletal muscle cultures, 3D Day 60 engineered skeletal muscle (ESM) and Day 60 skeletal muscle organoid (SMO)). (B) Unsupervised clustering (UMAP) of single-nucleus transcriptomes identifies 19 cell clusters. (C) Unsupervised clustering (UMAP) of single-nucleus transcriptomes to identify major cell groups based on enrichment of muscle, neural and mesenchymal genes. Muscle clusters are further specified as myogenic progenitors (MP), myoblasts (MB), satellite-like cell (SLC) and myonuclei (MN) based on transcriptional profiles indicated in (D). (D) Transcriptional profiles of the clusters separated by major cell groups (muscle, mesenchyme and neural). The relative contribution of the different samples to each cluster is indicated in the bar graphs. (E) Comparison of genes associated with secondary myogenesis and maturation in the myonuclei cluster (#3) between 2D Day 60, ESM Day 60 and SMO Day 60 samples.

We also found evidence of neuronal co-development during muscle differentiation. Day 22 cultures contained a PAX3⁺ neuronal progenitor population (#10), a developing LHX1⁺, DCX⁺ spinal cord neuron population (#13) and more matured NSG2⁺ and STMN2⁺ neurons (#18). Matured NSG2⁺ and STMN2⁺ neurons were still present in ESM (#9) and to a lower degree in 2D and SMO. These data indicate that the introduced differentiation protocol supports the generation of cell populations found in bona fide neuromuscular development.

Advancing muscle function in engineered skeletal muscle

To further enhance ESM maturation and given the low expression of MYH2 (Figure 3F) as well as the finding of a high thyroid hormone receptor expression (maturation cluster; Figure 2F), we hypothesized that triiodo-L-thyronine (T3) addition may enhance the transition of myosin heavy chain isoform expression towards adult fast myosin isoforms and increase tetanic force production.^{30,31} To test this hypothesis, we added T3 during maturation from Weeks 5 to 9 of ESM culture (Figure 5A).

T3 treatment did not influence the maximal twitch tension (Figure 5B), but clearly shortened the duration of single twitches of ESM. Accordingly, the speed of contraction (time to peak contraction—T1) of single twitches as well as relaxation (time to 50% relaxation—T2) at 9 weeks was significantly increased (Figure 5C). In addition, the rate of contraction and relaxation in tetanic contractions (100 Hz stimulation frequency) tended to be faster ($P = 0.18$) also in T3-treated ESM (Figure 5D).

The tetanus threshold (i.e., frequency where single twitches fuse to tetani) is greater in mammalian adult fast muscle fibre in comparison to slow muscle fibres. The tetanus threshold of ESM with and without T3 treatment was analysed by calculation of a fusion index (Figure S4). T3 induced with a shift towards higher stimulation frequencies (50% fusion at 3.92 ± 0.24 vs. 5.44 ± 0.05 Hz in control ESM vs. ESM + T3, respectively, $n = 8$; Figure S4). Collectively, these functional data suggest that T3 enhances fast muscle properties of ESM. In line with the functional phenotype, we found that T3 treatment enhanced the abundance of mature fast myosin heavy chain (MHC) isoform, whereas the embryonic MYH3 isoform was reduced. The abundance of the slow myosin isoform MYH7 remained unchanged (Figure 5E). These molecular changes suggest that T3 supports maturation of fast skeletal muscle properties in ESM. The data also demonstrate that ESMs respond to physiological stimuli comparable to skeletal muscle *in vivo*.

Enhanced functional maturation was associated with an advanced degree of structural maturation. Proteins of the DGC complex, such as β -dystroglycan and dystrophin, were

properly localized to the cell membrane (Figure 6A,B). Ultrastructural analysis by transmission electron microscopy showed advanced stages of myofibrillogenesis. Organized sarcomeres with distinct banding pattern including I bands, A bands, M lines and Z discs were observed, and mitochondria with dense matrix and developed cristae were found aligned with compact sarcomeres. In addition, membranous structures of the triad, composed of a central T-tubule surrounded by two terminal cisternae from the sarcoplasmic reticulum, were identified (Figure 6C).

Engineered skeletal muscles contain satellite-like cells with regenerative capacity

Even after prolonged *in vitro* culture, we found muscle stem cell transcripts in the differentiated skeletal muscle cultures predominantly in 3D in line with the single-nucleus sequencing data (Figure 7A). Immunostaining confirmed the presence of Pax7⁺ cells, $63 \pm 4\%$ ($n = 267$ cells counted) of which were located adjacent to a muscle fibre in ESM. The localization underneath the laminin⁺ basal lamina is indicative of a satellite cell position. Of note, $75 \pm 6\%$ ($n = 164$ cells counted) of these Pax7⁺ cells were Ki67⁻, confirming a quiescent state. In identically aged 2D monolayer cultures, only $32 \pm 5\%$ ($n = 105$ cells counted) of Pax7⁺ cells were associated with muscle fibres (Figure 7B). These data suggest that muscle cells in ESM self-organize into myofibres with adjacent satellite-like cells.

To test if the identified satellite cell-like niches in ESM are capable of muscle regeneration, we applied a well-established cardiotoxin (CTX) injury model (Figure 7C²⁷); 2 days after CTX injury, ESM did not generate measurable contractile forces, indicative of a complete loss of organized muscle fibres. After a regeneration period of 21 days, a partial, but robust recovery of contractile force (to $57 \pm 8\%$ of initial force, $n = 7$) was observed (Figure 7D). RNA expression data were in line with the functional data showing an almost complete loss of mature muscle transcript (*TTN*), whereas *PAX7* transcript was largely preserved 2 days after CTX injury (Figure 7E). Upregulation of Ki67 (*MKI67*) and *CDK1* indicated cell cycle activation 48 h post-injury coinciding with Myomixer (*MYMX*) and followed by Myomaker (*MYMK*) expression to indicate active fusion of myoblast progeny. Importantly, recovery of contractile force was paralleled by re-expression of *TTN* muscle transcript 21 days post-injury. Immunostaining confirmed the almost complete loss of mature myofibres with sparing of Pax7⁺ satellite-like cells 2 days after CTX injury. After 21 days of regeneration, substantial muscle was re-built (Figure 7F). Interestingly, we also observed an activation of MCs in ESM by CTX injury; 2 days post-injury, mesenchymal transcripts *EBF2* and *FAP* were increased (Figure S5A). This was associated with detection of Ki67⁺ in both Pax7⁺ and Pax7⁻ cell populations




Figure 5 Advancing engineered skeletal muscle (ESM) function by thyroid hormone treatment. (A) Experimental design: ESM maturation for 9 weeks with or without additional application of 0.1 μ mol/L triiodo-L-thyronine (T3) for 4 weeks. (B) Twitch tension in response to increasing stimulation frequencies of 9-week-old ESM cultured with (blue bars) or without T3 (black bars); $n = 7-10$ per group. (C) Quantification of contraction (T1) and relaxation (T2) time of single twitches of 9-week-old control (black bars) or +T3 (blue bars) ESM at 1 Hz (first panel); normalized representative traces of single twitches of 9-week-old control (black line) or +T3 (blue line) ESM at 1 Hz (second panel); $n = 5-11$ per group, $^*P < 0.05$ by unpaired, two-sided Student's t test. (D) Rate of force development (RFD; rate of contraction: dTT/dt+ and rate of relaxation: dTT/dt-) of 9-week-old control (black bars) or +T3 (blue bars) ESM at 100 Hz tetanus (first panel); representative traces of twitch tension of 9-week-old control (black line) or +T3 (blue line) ESM at 100 Hz tetanus (fourth panel); $n = 4-11$ per group, $^*P < 0.05$ by unpaired, two-tailed Student's t test. (E) Immunoblot for fast myosin heavy chain (MHC) isoforms, slow MHC (MYH7), embryonic MHC (MYH3) and loading control vinculin (VCL). Protein abundance of fast MHC (left panel), MYH7 (middle panel) and MYH3 (right panel) in 9-week-old ESM cultured with (blue bars) or without T3 (black bars); $n = 3$ per group, $^*P < 0.05$ by unpaired, two-tailed Student's t test

(Figure S5B). To test if the cell cycle activation of satellite-like cells is required for ESM regeneration, we inhibited cell cycle activity by irradiation with 30 Gy. This completely abolished the regenerative response and formation of new

muscle fibres (Figure S6). Note that irradiation of uninjured muscle did not impact contractile force. Those data demonstrate that functional muscle regeneration can be modelled in ESM.




Figure 6 Maturation of muscle structure in engineered skeletal muscle (ESM). (A) Immunostaining of β -dystroglycan (magenta) in the sarcolemma of actin⁺ muscle fibres (green) in an ESM cross section. Scale bar: 40 μ m. (B) Immunostaining of dystrophin (magenta) in the sarcolemma of actinin⁺ muscle fibres (green) in an ESM cross section. Scale bar: 30 μ m. (C) Transmission electron microscopy (TEM) images of sarcomere ultrastructure, T-tubular triads and mitochondria along the muscle fibres in ESM. M, M line; Mt, mitochondria; TT, T-tubule. Scale bar: 1 μ m (left and middle panels) and 250 nm (right panel)

Myoediting rescues contractile dysfunction of Duchenne muscular dystrophy engineered skeletal muscle

To investigate if ESMs recapitulate contractile dysfunction of DMD, we generated ESMs from a patient-derived iPSC line with a large exon 48–50 deletion (Del), leading to a premature stop codon in exon 51.³² This was compared to an isogenic control where the DMD reading frame was restored by CRISPR/Cas9-mediated destruction ('myoediting') of the splice acceptor site of exon 51 (Del-Cor, Figure S6³²). The absence of dystrophin protein did not have an impact on skeletal myocyte differentiation (Figures 8A and S2). We confirmed the absence of dystrophin in 2D differentiated skeletal myocytes and ESM from Del myocytes as well as its restoration after myoediting by immunostaining and western blot analyses (Figure 8B–D). Loss of dystrophin was

associated with a reduction of fast MHC expression in DMD ESM in line with early reports on predominant affection of fast MHC-expressing fibres in DMD muscles (Figure 8D^{33,34}). Total muscle content measured by α -actinin was only slightly reduced ($-13 \pm 2\%$, $n = 3$, $P < 0.05$) in DMD ESM (Figure 8D). Importantly, loss of dystrophin and reduction of fast MHC resulted in reduced twitch tension ($-35 \pm 7\%$ at 100 Hz tetanus, $n = 8$, $P < 0.05$) and prolonged contraction and relaxation times demonstrating that ESM culture unmasks early changes of DMD myopathy (Figure 8E,F).

Discussion

We report a novel model for human skeletal muscle derivation in 2D and 3D organoid (SMO) cultures as well as for the engineering of skeletal muscle (ESM) with ad-




Figure 7 Regenerative capacity of human engineered skeletal muscle. (A) RNA transcript (reads per kilobase million [RPKM]) of indicated muscle stem cell markers in 2D monolayer cells at Day 22 and Day 60, plus Day 60 ESM; $n = 3-4$ per group, $^*P < 0.05$ by one-way analysis of variance (ANOVA) and Tukey's multiple comparison test. (B) Immunostaining of longitudinal sections of Day 60 ESM for laminin (magenta), Ki67 (magenta), actin (green), PAX7 (grey) and nuclei (blue). Scale bars: 10 μm . Immunostaining of laminin (magenta), PAX7 (grey), actin (green) and nuclei (blue) in 2D monolayer cultures at Day 60. Scale bar: 50 μm . (C) Experimental design of cardiotoxin (CTX) injury model. ESMs were incubated with 25 $\mu\text{g}/\text{mL}$ CTX for 24 h. (D) Tetanic twitch tension at 100 Hz stimulation frequency of ESM at indicated time points after CTX (25 $\mu\text{g}/\text{mL}$) injury or control (Ctrl) condition; $n = 7-8$ per group, $^*P < 0.05$ versus the respective Ctrl Day +2, by one-way ANOVA and Tukey's multiple comparison test, $^{\#}P < 0.05$ CTX Day +2 versus CTX Day +21. (E) RNA transcript abundance for indicated genes at early (d+2) and late (d+21) time points after CTX (25 $\mu\text{g}/\text{mL}$) injury or control (Ctrl) conditions; $n = 3$, $^*P < 0.05$ by one-way ANOVA and Tukey's multiple comparison test. (F) Immunostaining of sarcomeric α -actinin (green), PAX7 (grey) and nuclei (blue) in ESM at indicated time points. Scale bars: 50 μm




Figure 8 Modelling Duchenne muscular dystrophy in engineered skeletal muscle (ESM). (A) Immunostaining of sarcomeric α -actinin (green) and nuclei of 2D monolayer skeletal muscle cells at Day 22 from Del and Del-Cor lines. Scale bar: 50 μ m. (B) Immunoblot for dystrophin in WT, Del and Del-Cor skeletal myocytes. Vinculin serves as loading control. (C) Immunostaining of 5-week-old ESM cross sections for dystrophin (magenta), α -actinin (green) and nuclei (blue). Scale bar: 20 μ m. (D) Immunoblot of ESM for α -actinin, dystrophin and fast myosin heavy chain. Vinculin serves as loading control. Quantification of protein data, $n = 3$, $P < 0.05$ by unpaired, two-sided Student's t test. (E) Twitch tension in response to increasing stimulation frequencies of 5-week-old Del-ESM (black bars) and Del-Cor ESM (blue bars), $n = 8$ per group, $P < 0.05$ by two-way analysis of variance (ANOVA) and Tukey's multiple comparison test. (F) Quantification of contraction (T1) and relaxation (T2) times of single twitches of 5-week-old Del-ESM (black bars) or Del-Cor ESM (blue bars) ESM at 1 Hz. $*P < 0.05$ by unpaired, two-sided Student's t test

vanced structural and functional properties. Our data suggest that multicellularity (including neurons and supporting mesenchyme) and three-dimensionality are key for in vitro skeletal muscle development with in vivo properties. The re-engineering of a regeneration-competent satellite-like cell niche appears particularly interesting as it may not only offer a solution for disease modelling and drug screening but also for stable culture and amplification of muscle stem cells for regenerative applications (as demonstrated previously for the rat model²⁷). The demonstration of en-

hanced maturation of the developed muscle model under T3 supplementation and uncovering of a DMD phenotype further demonstrate the applicability as a screening tool for maturation advancing factors and preclinical therapies in vitro.

In contrast to myogenic transcription factor overexpression models,^{4–10} we directed differentiation in 2D monolayer culture and 3D organoids using defined and developmentally inspired growth factors and small molecules. The strength of this approach is potential control over the developmental or-

igin of resulting muscle. Following the induction of paraxial mesoderm, we demonstrated that maintaining FGF signalling in the presence of Notch inhibition (DAPT) induces a hypaxial dermomyotome pattern during *in vitro* somitogenesis between Days 8 and 13 with predominant expression of PAX3 and SIM1 but little EN1. EN1 expression increases at later time points in both 2D and 3D cultures consistent with its role in limb formation.³⁵ The predominant development into limb muscle was further supported by increase in transcript and protein of migratory limb progenitors (*LBX1* and *MET*). Further dissecting and controlling developmental origin of muscle *in vitro* will be important to faithfully recapitulate disease states of particular muscle compartments (e.g., limb and diaphragm in DMD).

Although the SMO model, to our knowledge the first human SMO model with bona fide muscle function, allows for a simulation of embryonic muscle development, our data demonstrate that more classical tissue engineering models, such as applied for the generation of ESM, are more likely to achieve higher levels of organotypic maturation. ESM demonstrated higher myofibre diameter, clear anisotropic structure with membrane localized DGC, advanced ultrastructural properties (e.g., Z, I, A, H and M bands and T-tubules) and ~2-fold higher tetanic forces.

Despite the advanced organotypic properties, it is important to point out that the observed contractile parameters in ESM are not fully representative of adult skeletal muscle. For example, myofibres in ESM present with a smaller average muscle cell diameter (0.2- to 0.3-fold), a still rather foetal myosin isoform expression pattern (high MYH3 to MYH2 ratio), ~10% of the maximal contractile force reported for adult muscle, predominantly central nuclei and a high number of progenitor cells (PAX7⁺). Strategies to enhance physiological hypertrophic growth are needed to further enhance skeletal muscle properties. Increased fast MYH2 and reduced MYH3 expression under exposure to T3 represent first proof of concept for the propensity of ESM to undergo further maturation if exposed to supportive stimuli. In this context, it is important to emphasize that the introduced fully serum-free process will be advantageous for the testing of additional maturation factors.

We further demonstrate that the ESM model uncovers an apparent early developmental defect in DMD with reduction of fast myosin isoforms compared to the corrected isogenic line with dystrophin protein expression. This was associated with prolonged contraction and relaxation times in DMD muscle as well as reduced contractile force, supporting recent findings in functionalized monolayer cultures of DMD muscle cells.²² Importantly, in this model, we could clearly demonstrate the 'therapeutic' effect of CRISPR/Cas9-based myoediting, demonstrating the general utility of ESM for the preclinical assessment of gene therapy strategies in myopathies.

Finally, the observation of regeneration in ESM after CTX-induced damage in dependence of PAX7⁺ satellite-like cell function was particularly notable, because it demonstrates that regeneration-competent satellite-like cells can be developed using the reported protocol. The recovery of twitch force is a comprehensive readout of regeneration as it integrates diverse aspects of the regenerative response, for example, activation and proliferation of muscle stem cells, fusion of myoblasts, maturation of regenerating fibres, but also 'regenerative crosstalk' to MCs, neurons or immune cells. The robust but incomplete recovery of twitch force after CTX injury needs further clarification but may point to the developmental status of ESM with a foetal stage of PAX7⁺ satellite cell development without the full regenerative potential of quiescent adult satellite cells that typically evolve after birth.³⁶

The regeneration of engineered muscle by satellite-like cell activation is fascinating and has only recently been observed for human muscle *in vitro*.³⁷ Fleming et al. used primary muscle cells similar to earlier work in the rat^{27,38} and a BaCl₂ injury model, which may partially spare myotubes, leaving the possibility for PAX7⁺ cell-independent regeneration.³⁹ To avoid this limitation, we have carefully titrated CTX to destroy most if not all developed myofibres, while sparing only and most of the PAX7⁺ cells. The following sequelae of PAX7⁺ cell activation, proliferation and fusion were completely inhibited by irradiation, which supports a true regenerative pattern.

We conclude that the skeletal muscle differentiation protocols in monolayer culture and in a novel organoid format (SMO) as well as the demonstration of skeletal muscle tissue engineering (ESM) as a means to enhance maturation provide innovative platforms to study human skeletal muscle development, disease and regeneration in a simple and robust *in vitro* model.

Acknowledgements

M.T. is supported by the German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislaufforschung [DZHK]) and the German Research Foundation (Deutsche Forschungsgemeinschaft) (DFG TI 956/1-1 and SFB 1002 TP C04). W-H.Z. is supported by the DZHK (German Centre for Cardiovascular Research), the German Federal Ministry for Science and Education (IndiHEART; 161L0250A), the German Research Foundation (DFG SFB 1002 C04/S01, IRTG 1816 and MBExC 2067) and the Fondation Leducq (20CVD04). Part of the work was supported by the French Muscular Dystrophy Association (Association Française contre les Myopathies [AFM], Project No. 20987) to J.S. J.Z. and J.S. are members of the European reference network for neuromuscular disorders (ERN EURO-NMD). We acknowledge A.K. Hell and H.M.

Lorenz for providing human skeletal muscle samples. Expert technical assistance by Iris Iben is gratefully acknowledged. We acknowledge Xingbo Xu, Susanne Burkhardt and Ranjit Pradhan for excellent technical support of the single-nucleus sequencing experiments. We thank J.V. Dürr for support with BioRender figures. Generation of the GMP line LiPSC-GR1.1 (also known as TC1133 or RUCDRi002-A) was supported by the NIH Common Fund Regenerative Medicine Program. The NIH Common Fund and the National Center for Advancing Translational Sciences (NCATS) are joint stewards of the LiPSC-GR1.1 resource. The TC1133 line (Master Cell Bank Lot No. 50-001-21) was acquired by Repairon GmbH from the National Institute of Neurological Disorders and Stroke (NINDS) Human Cell and Data Repository (NHCDR) and processed to a GMP working cell bank (WCB). Post-production cells from the WCB were kindly provided by Repairon GmbH to UMG for research use. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.⁴⁰

Open Access funding enabled and organized by Projekt DEAL. WOA Institution: GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN Consortia Name : Projekt DEAL

Conflicts of interest

The University of Göttingen has filed a patent on skeletal muscle generation listing M. Shahriyari, W-H.Z. and M.T. as inventors (WO 2021/074126A1). W-H.Z. is founder, shareholder and advisor of Myriamed GmbH, MyriaMeat GmbH and Repairon GmbH. M.T. is founder of MyriaMeat GmbH and advisor of Myriamed GmbH and Repairon GmbH.

Online supplementary material

Additional supporting information may be found online in the Supporting Information section at the end of the article.

References

- Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 1987;**51**: 987–1000.
- Striedinger K, Barruet E, Pomerantz JH. Purification and preservation of satellite cells from human skeletal muscle. *STAR Protoc* 2021;**2**:100302.
- Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A, et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. *Skelet Muscle* 2011;**1**:34.
- Kim J, Magli A, Chan SSK, Oliveira VKP, Wu J, Darabi R, et al. Expansion and purification are critical for the therapeutic application of pluripotent stem cell-derived myogenic progenitors. *Stem Cell Rep* 2017;**9**: 12–22.
- Darabi R, Arpke RW, Irion S, Dimos JT, Grskovic M, Kyba M, et al. Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. *Cell Stem Cell* 2012;**10**:610–619.
- Rao L, Qian Y, Khodabukus A, Ribar T, Bursac N. Engineering human pluripotent stem cells into a functional skeletal muscle tissue. *Nat Commun* 2018;**9**:126.
- Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. *Cell Stem Cell* 2016;**18**:533–540.
- Tedesco FS, Gerli MF, Perani L, Benedetti S, Ungaro F, Cassano M, et al. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. *Sci Transl Med* 2012;**4**:140ra89.
- Albini S, Coutinho P, Malecova B, Giordani L, Savchenko A, Forcales SV, et al. Epigenetic reprogramming of human embryonic stem cells into skeletal muscle cells and generation of contractile myospheres. *Cell Rep* 2013;**3**:661–670.
- Goudenege S, Lebel C, Huot NB, Dufour C, Fujii I, Gekas J, et al. Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation. *Mol Ther* 2012;**20**:2153–2167.
- Shelton M, Metz J, Liu J, Carpenedo RL, Demers SP, Stanford WL, et al. Derivation and expansion of PAX7-positive muscle progenitors from human and mouse embryonic stem cells. *Stem Cell Rep* 2014;**3**: 516–529.
- Chal J, al Tanoury Z, Hestin M, Gobert B, Aivio S, Hick A, et al. Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro. *Nat Protoc* 2016;**11**:1833–1850.
- Xi H, Fujiwara W, Gonzalez K, Jan M, Liebscher S, van Handel B, et al. In vivo human somitogenesis guides somite development from hPSCs. *Cell Rep* 2017;**18**: 1573–1585.
- Choi IY, Lim H, Estrellas K, Mula J, Cohen TV, Zhang Y, et al. Concordant but varied phenotypes among Duchenne muscular dystrophy patient-specific myoblasts derived using a human iPSC-based model. *Cell Rep* 2016;**15**:2301–2312.
- Caron L, Kher D, Lee KL, McKernan R, Dumevska B, Hidalgo A, et al. A human pluripotent stem cell model of facioscapulohumeral muscular dystrophy-affected skeletal muscles. *Stem Cells Transl Med* 2016;**5**:1145–1161.
- Borchin B, Chen J, Barberi T. Derivation and FACS-mediated purification of PAX3+/PAX7+ skeletal muscle precursors from human pluripotent stem cells. *Stem Cell Rep* 2013;**1**:620–631.
- Chal J, Oginuma M, al Tanoury Z, Gobert B, Sumara O, Hick A, et al. Differentiation of pluripotent stem cells to muscle fiber to model Duchenne muscular dystrophy. *Nat Biotechnol* 2015;**33**:962–969.
- Faustino Martins JM, Fischer C, Urzi A, Vidal R, Kunz S, Ruffault PL, et al. Self-organizing 3D human trunk neuromuscular organoids. *Cell Stem Cell* 2020;**27**:498.
- Mazaleyrat K, Badja C, Broucqsaault N, Chevalier R, Laberthonnière C, Dion C, et al. Multilineage differentiation for formation of innervated skeletal muscle fibers from healthy and diseased human pluripotent stem cells. *Cell* 2020;**9**:1531.
- Steele-Stallard HB, Pinton L, Sarcar S, Ozdemir T, Maffioletti SM, Zammit PS, et al. Modeling skeletal muscle laminopathies using human induced pluripotent stem cells carrying pathogenic LMNA mutations. *Front Physiol* 2018;**9**:1332.
- Maffioletti SM, Sarcar S, Henderson ABH, Mannhardt I, Pinton L, Moyle LA, et al. Three-dimensional human iPSC-derived artificial skeletal muscles model muscular dystrophies and enable multilineage tissue engineering. *Cell Rep* 2018;**23**:899–908.
- al Tanoury Z, Zimmerman JF, Rao J, Sieiro D, McNamara HM, Cherrier T, et al. Prednisolone rescues Duchenne muscular dystrophy phenotypes in human pluripotent

- stem cell-derived skeletal muscle in vitro. *Proc Natl Acad Sci U S A* 2021;**118**: e2022960118.
23. Uchimura T, Asano T, Nakata T, Hotta A, Sakurai H. A muscle fatigue-like contractile decline was recapitulated using skeletal myotubes from Duchenne muscular dystrophy patient-derived iPSCs. *Cell Rep Med* 2021;**2**:100298.
 24. Mournetas V, Massouridès E, Dupont JB, Kornobis E, Polvêche H, Jarrige M, et al. Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset. *J Cachexia Sarcopenia Muscle* 2021;**12**: 209–232.
 25. Afshar Bakooshli M, Lippmann ES, Mulcahy B, Iyer N, Nguyen CT, Tung K, et al. A 3D culture model of innervated human skeletal muscle enables studies of the adult neuromuscular junction. *Elife* 2019;**8**.
 26. Xu B, Zhang M, Perlingeiro RCR, Shen W. Skeletal muscle constructs engineered from human embryonic stem cell derived myogenic progenitors exhibit enhanced contractile forces when differentiated in a medium containing EGM-2 supplements. *Adv Biosyst* 2019;**3**:e1900005.
 27. Tiburcy M, Markov A, Kraemer LK, Christalla P, Rave-Fraenk M, Fischer HJ, et al. Regeneration competent satellite cell niches in rat engineered skeletal muscle. *FASEB Bioadv* 2019;**1**:731–746.
 28. Loh KM, Chen A, Koh PW, Deng TZ, Sinha R, Tsai JM, et al. Mapping the pairwise choices leading from pluripotency to human bone, heart, and other mesoderm cell types. *Cell* 2016;**166**:451–467.
 29. Cheng L, Alvares LE, Ahmed MU, El-Hanfy AS, Dietrich S. The epaxial–hypaxial subdivision of the avian somite. *Dev Biol* 2004;**274**:348–369.
 30. Larsson L, Li X, Teresi A, Salviati G. Effects of thyroid hormone on fast- and slow-twitch skeletal muscles in young and old rats. *J Physiol* 1994;**481**:149–161.
 31. Schiaffino S, Ausoni S, Gorza L, Saggin L, Gundersen K, Lomo T. Myosin heavy chain isoforms and velocity of shortening of type 2 skeletal muscle fibres. *Acta Physiol Scand* 1988;**134**:575–576.
 32. Long C, Li H, Tiburcy M, Rodriguez-Caycedo C, Kyrychenko V, Zhou H, et al. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. *Sci Adv* 2018;**4**:eaap9004.
 33. Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. *Cell* 1988;**52**:503–513.
 34. Rafael JA, Townsend ER, Squire SE, Potter AC, Chamberlain JS, Davies KE. Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. *Hum Mol Genet* 2000;**9**:1357–1367.
 35. Allou L, Balzano S, Magg A, Quinodoz M, Royer-Bertrand B, Schöpflin R, et al. Non-coding deletions identify Maenli lncRNA as a limb-specific En1 regulator. *Nature* 2021;**592**:93–98.
 36. Gattazzo F, Laurent B, Relaix F, Rouard H, Didier N. Distinct phases of postnatal skeletal muscle growth govern the progressive establishment of muscle stem cell quiescence. *Stem Cell Rep* 2020;**15**: 597–611.
 37. Fleming JW, Capel AJ, Rimington RP, Wheeler P, Leonard AN, Bishop NC, et al. Bioengineered human skeletal muscle capable of functional regeneration. *BMC Biol* 2020;**18**:145.
 38. Juhas M, Engelmayer GC Jr, Fontanella AN, Palmer GM, Bursac N. Biomimetic engineered muscle with capacity for vascular integration and functional maturation in vivo. *Proc Natl Acad Sci U S A* 2014;**111**:5508–5513.
 39. Roman W, Pinheiro H, Pimentel MR, Segalés J, Oliveira LM, García-Domínguez E, et al. Muscle repair after physiological damage relies on nuclear migration for cellular reconstruction. *Science* 2021;**374**: 355–359.
 40. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. *J Cachexia Sarcopenia Muscle* 2021;**12**:2259–2261.